Statins for multiple sclerosis

Wang, Jin; Xiao, Yang; Luo, Man; Zhang, Xianlong; Luo, Hui

doi:10.1002/14651858.cd008386

Cited by 7 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2012–2013, 39.2 million individuals—accounting for 221 million prescriptions—were using statins, generating $16.9 billion in U.S. sales 24 . Multiple studies report an association between statin use and AD, 10–13,20 dementia, 7,21,25,26 MS, 27,28 PD, 29,30 and ALS 31,32 . Current meta‐analyses for AD, 21,33 dementia, 21 MS, 34 PD, 35 and ALS 36 suggest that statin use is associated with NDD risk decrements, except for ALS—as the evidence is insufficient to draw any conclusion—and all call for the addition of further studies to add to the existent literature.…”

Section: Introductionmentioning

confidence: 99%

Statin therapy and risk of Alzheimer's and age‐related neurodegenerative diseases

Torrandell‐Haro

Branigan

Vitali

et al. 2020

A&D Transl Res & Clin Interv

View full text Add to dashboard Cite

Introduction Establishing efficacy of and molecular pathways for statins has the potential to impact incidence of Alzheimer's and age‐related neurodegenerative diseases (NDD). Methods This retrospective cohort study surveyed US‐based Humana claims, which includes prescription and patient records from private‐payer and Medicare insurance. Claims from 288,515 patients, aged 45 years and older, without prior history of NDD or neurological surgery, were surveyed for a diagnosis of NDD starting 1 year following statin exposure. Patients were required to be enrolled with claims data for at least 6 months prior to first statin prescription and at least 3 years thereafter. Computational system biology analysis was conducted to determine unique target engagement for each statin. Results Of the 288,515 participants included in the study, 144,214 patients (mean [standard deviation (SD)] age, 67.22 [3.8] years) exposed to statin therapies, and 144,301 patients (65.97 [3.2] years) were not treated with statins. The mean (SD) follow‐up time was 5.1 (2.3) years. Exposure to statins was associated with a lower incidence of Alzheimer's disease (1.10% vs 2.37%; relative risk [RR], 0.4643; 95% confidence interval [CI], 0.44–0.49; P < .001), dementia 3.03% vs 5.39%; RR, 0.56; 95% CI, 0.54–0.58; P < .001), multiple sclerosis (0.08% vs 0.15%; RR, 0.52; 95% CI, 0.41–0.66; P < .001), Parkinson's disease (0.48% vs 0.92%; RR, 0.53; 95% CI, 0.48–0.58; P < .001), and amyotrophic lateral sclerosis (0.02% vs 0.05%; RR, 0.46; 95% CI, 0.30–0.69; P < .001). All NDD incidence for all statins, except for fluvastatin (RR, 0.91; 95% CI, 0.65‐1.30; P = 0.71), was reduced with variances in individual risk profiles. Pathway analysis indicated unique and common profiles associated with risk reduction efficacy. Discussion Benefits and risks of statins relative to neurological outcomes should be considered when prescribed for at‐risk NDD populations. Common statin activated pathways indicate overarching systems required for risk reduction whereas unique targets could advance a precision medicine approach to prevent neurodegenerative diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Statin therapy and risk of Alzheimer's and age‐related neurodegenerative diseases

Torrandell‐Haro

Branigan

Vitali

et al. 2020

A&D Transl Res & Clin Interv

View full text Add to dashboard Cite

show abstract

“…Three‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (statins) have been theorized to have neuroprotective effects in neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases . In HD animal models, statins are known to upregulate nitric oxide synthase, reduce the inflammatory response, and decrease oxidative stress .…”

mentioning

confidence: 99%

Statin use and delayed onset of Huntington's disease

et al. 2018

View full text Add to dashboard Cite

Background There is evidence to suggest that 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase inhibitors (statins) may be beneficial in Huntington's disease (HD). Objective This study aimed to determine if statin use was associated with delayed motor diagnosis in participants with premotor HD. Methods Among premotor HD participants from the Enroll‐HD database, statin users were propensity score matched with statin nonusers based on cytosine‐adenine‐guanine–age product score, cytosine‐adenine‐guanine repeat length, baseline age, sex, and region. A Cox regression survival analysis compared the annualized hazard ratio (HR) of receiving a motor diagnosis between the 2 groups. Results The annualized HR of progressing to an HD motor diagnosis was lower in the statin users (n = 89) when compared with the statin nonusers (n = 89; HR = 0.27 [95% CI 0.18‐0.50], P < .0001). Conclusions In patients with premotor HD, statin use was associated with a delayed motor diagnosis of HD. Further studies are warranted to investigate if statins would be an effective disease‐modifying therapy for HD. © 2018 International Parkinson and Movement Disorder Society

show abstract

“…5 Two meta-analyses of statins (atorvastatin and simvastatin) examining the same trials found that there was no benefi t of statins in regard to MS relapse rates, disease progression, or change in disability scores. 8,9 Meta-analyses A meta-analysis evaluating the effi cacy of statins in combination with interferon therapy for the management of patients with relapsing remitting MS identifi ed 4 unique randomized controlled trials. The evaluated statins included simvastatin and atorvastatin, with 2 studies each.…”

Section: Resultsmentioning

confidence: 99%

Section: Therapy Considerationsmentioning

confidence: 99%

Atorvastatin: Multiple Sclerosis

Generali

Cada²

2014

Hosp Pharm

View full text Add to dashboard Cite

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

show abstract

Statins for multiple sclerosis

Cited by 7 publications

References 19 publications

Statin therapy and risk of Alzheimer's and age‐related neurodegenerative diseases

Statin therapy and risk of Alzheimer's and age‐related neurodegenerative diseases

Statin use and delayed onset of Huntington's disease

Atorvastatin: Multiple Sclerosis

Contact Info

Product

Resources

About